NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
Sign in Subscribe

Amid Nasdaq’s Worst Week in a Year, Three New Listings Stand Out

Two biotech IPOs and an AI infrastructure stock rose sharply on their early trading days even as the Nasdaq tumbled on broader tech weakness.

Amid Nasdaq’s Worst Week in a Year, Three New Listings Stand Out
Credit: Iambic Therapeutics
Already have an account? Sign in.
10/16/2026 · 4:42 PM
IAM
/ Read more

Feed↓

Hims & Hers Shares Fall After Missing Revenue and Subscriber Expectations
Featured/ 11/09/2026 · 5:16 PM

Hims & Hers Shares Fall After Missing Revenue and Subscriber Expectations

Hims & Hers stock drops after missing revenue and subscriber expectations. Q3 revenue rose 49% to $890M, but margins compressed and guidance tightened.

/ Subscriber only
Rocket Lab Posts Record Q3 Revenue and $3.57B Backlog, but Shares Fall After Earnings Miss
Featured/ 11/09/2026 · 4:41 PM

Rocket Lab Posts Record Q3 Revenue and $3.57B Backlog, but Shares Fall After Earnings Miss

Rocket Lab posted record $268M Q3 revenue and a $3.57B backlog, but shares dropped 5% after a wider-than-expected EPS miss.

/ Subscriber only
Investors Sell Janux Shares After Initial Clinical Data Falls Short of Differentiation Expectations
11/09/2026 · 3:29 PM

Investors Sell Janux Shares After Initial Clinical Data Falls Short of Differentiation Expectations

The biotech’s initial JANX011 Phase 1 results in healthy volunteers triggered a sharp selloff as investors questioned near-term value and differentiation.

/ Subscriber only
Explore
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
More
  • Sign up
  • Sign in
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Terms/Privacy
  • UP↑
Get alerts

Be the first to know when deals break, stocks move, or biotech headlines hit.

Email address Subscribe
DON'T FALL BEHIND. ©2026
For informational purposes only. Not financial advice.
NOTRELOAD AI